Preventing adverse obstetric outcomes in women with genetic thrombophilia.
OBJECTIVE
To improve fetomaternal outcomes in women with obstetric complications and inherited causes of thrombophilia.


METHODS
Clinical trial.


METHODS
Thrombophilic women with previous unexplained adverse outcomes.


METHODS
Twenty-five women with previous severe obstetric complications were treated during and after pregnancy.


METHODS
Low fixed dose of heparin or aspirin.


METHODS
Fetomaternal outcome.


RESULTS
Low fixed dose of heparin were administered to 24 pregnant women, aspirin to 7. Overall, among 31 treated pregnant women, 28 (90.3%) compared to 4 of 58 (6.9%) in previous pregnancies had a good obstetric outcome. Two fetal losses <14 weeks gestation and a fetal growth restriction were registered. All newborns, except one, were in the tenth centile or above. All babies were discharged in good clinical status. In the treated pregnancies, no thrombosis or pharmacological side effect was recorded.


CONCLUSIONS
Heparin prophylaxis at fixed low doses and possibly aspirin could be efficacious in preventing adverse outcomes in women carrying inherited thrombophilia with previous poor obstetric outcomes.
Atherosclerosis and Thrombosis Unit, Casa Sollievo della Sofferenza, S. Giovanni R. (Foggia), Italy. ate.tro@operapadrepio.it
Elvira
E
Grandone
Vincenzo
V
Brancaccio
Donatella
D
Colaizzo
Natale
N
Sciannamé
Giuseppe
G
Pavone
Giovanni
G
Di Minno
Maurizio
M
Margaglione
D001241:Aspirin / Q000627:therapeutic use*; D017984:Enoxaparin / Q000627:therapeutic use; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy*; D011256:Pregnancy Outcome; D019851:Thrombophilia / Q000188:drug therapy*
D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006493:Heparin; D001241:Aspirin